Background: Fatigue and pruritus are common and disabling in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), but their severity is not reliably explained by standard biochemical markers. Whether liver stiffness measured by transient elastography reflects these symptoms remains unclear. This study examined associations between liver stiffness and fatigue and pruritus in PBC and PSC, and between routine biochemical measures and symptom burden. Methods: This cross-sectional analysis included 107 patients (56 PBC, 51 PSC) from a prospective autoimmune liver disease registry. Fatigue was assessed with the CLDQ-29 fatigue domain and pruritus with the CLDQ-29 pruritus item or the itch visual analog scale. Multivariable linear and ordered logistic regression examined associations between liver stiffness and fatigue and pruritus, adjusted for disease type, age, and sex. Spearman correlations assessed associations between liver stiffness and clinical and laboratory variables, with Benjamini–Hochberg correction. Receiver operating characteristic analysis assessed discrimination. Results: Patients with PBC were older (59 vs. 51 years; p < 0.001) and more often female (96.4% vs. 56.9%; p < 0.001) than those with PSC. Liver stiffness (6.0 vs. 6.8 kPa; p = 0.101), fatigue scores, pruritus scores, and itch VAS were similar between groups. Liver stiffness was not associated with fatigue (β = 0.005; p = 0.835) or pruritus (OR = 0.97; p = 0.190) after adjustment; only age was associated with fatigue (β = 0.021; p = 0.020). Among laboratory measures, only ALP remained correlated with liver stiffness after correction (ρ = 0.309; adjusted p = 0.027). In PSC alone, higher liver stiffness was associated with worse pruritus (ρ = −0.37; p = 0.009), a finding not seen in PBC. Liver stiffness alone showed limited discrimination for fatigue (AUC 0.46) and pruritus (AUC 0.56); a model with disease type, age, and sex improved discrimination modestly for fatigue (AUC 0.60) but not for pruritus (AUC 0.57). Conclusions: Liver stiffness was not associated with fatigue or pruritus in the overall cohort of patients with PBC and PSC, and a possible association with pruritus in PSC needs confirmation. Patient-reported outcomes should be assessed alongside biochemical and elastographic measures, and how they relate to objective measures of disease remains an open question.
19 June 2026 in Turkish Journal of Gastroenterology
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases characterized by bile duct injury that may progress to fibrosis, cirrhosis, liver failure, and malignancy and ultimately require liver transplantation. Although these diseases share several clinical features, they differ substantially in pathogenesis, clinical course, and therapeutic approaches. Ursodeoxycholic acid remains the standard first-line therapy for PBC; patients with an inadequate biochemical response may be treated with second-line agents such as seladelpar, elafibranor, or fibrates. In contrast, no approved therapy has been shown to slow disease progression in PSC. Emerging therapies primarily target symptom and complication management, and overall management focuses on surveillance and timely referral for liver transplantation. This review summarizes current approaches to risk assessment, treatment, symptom management, monitoring, and transplantation decision-making in both conditions. Cite this article as: Abadi-Ron V, Marenco-Flores A, Rojas-Amaris N, et al. Current treatment of primary biliary cholangitis and primary sclerosing cholangitis: A comprehensive review. Turk J Gastroenterol. Published online June 19, 2026. doi: 10.5152/tjg.2026.26267
Autoimmune liver diseases (AILD), including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), can significantly influence patients' health-related quality of life (HRQOL). Understanding longitudinal HRQOL trends and associated factors may help identify patients at risk for poor HRQOL long-term. This longitudinal, single-center observational study aimed to assess longitudinal changes in HRQOL and identify baseline factors associated with HRQOL over time among patients with AILD. Adult patients with AIH, PBC, and/or PSC enrolled in a single-center prospective autoimmune liver registry were included. HRQOL was assessed using the Chronic Liver Disease Questionnaire (CLDQ). Linear mixed-effects models evaluated longitudinal changes in HRQOL and identified baseline demographic and clinical factors associated with HRQOL. A total of 252 patients (mean follow-up=35.3±23.5 months) were included. At baseline, CLDQ total scores indicated relatively preserved HRQOL (mean=5.47±1.04) and showed a small but statistically significant increase over time (β=0.0018, p=0.03). The emotional and worry domains demonstrated modest improvement, whereas other domains remained stable. Male sex was associated with higher HRQOL (β=0.33, p=0.04), while the presence of other autoimmune diseases (β=-0.34, p=0.01), coexisting metabolic-associated steatotic liver disease (β=-0.39, p=0.04), and ascites (β=-1.24, p=0.002) were associated with poorer HRQOL over time. While HRQOL among patients with AILD remained largely stable over time, patients with other autoimmune and liver conditions experience lower HRQOL. These findings underscore the importance of identifying high-risk patients and providing tailored strategies to maintain and improve long-term HRQOL in this population.